Morbidity of chronic hepatitis C as seen in a tertiary care medical center

被引:87
作者
Lee, DH
Jamal, H
Regenstein, FG
Perrillo, RP
机构
[1] ALTON OCHSNER MED FDN & OCHSNER CLIN, DEPT INTERNAL MED, NEW ORLEANS, LA 70121 USA
[2] ALTON OCHSNER MED FDN & OCHSNER CLIN, SECT GASTROENTEROL & HEPATOL, NEW ORLEANS, LA 70121 USA
关键词
hepatitis C; morbidity;
D O I
10.1023/A:1018818012378
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We studied the morbidity of chronic hepatitis C in patients referred to a tertiary care medical facility. The medical records of 500 consecutive cases of chronic hepatitis C were examined for the following: (1) source and time of exposure, (2) signs and symptoms of liver disease, (3) degree of alcohol intake, (4) liver biopsy findings, (5) extrahepatic disease manifestations, and (6) coexisting illnesses that could have an impact on morbidity. Morbidity and histologic findings were evaluated in relation to the duration of hepatitis C. The onset of infection could be determined in 376 patients (75%). A dose relationship between the length of infection and disease features was not observed. Fatigue was common at all stages of infection. Whereas cirrhosis occurred more frequently in patients with disease of long duration, 15-24% of patients had signs of advanced liver disease (ascites, encephalopathy, thrombocytopenia) within six years of exposure. Overt extrahepatic manifestations of chronic hepatitis C occurred infrequently, and depression was reported in 24% of untreated patients. In conclusion, in patients referred to a tertiary care setting, chronic hepatitis C is often associated with significant morbidity.
引用
收藏
页码:186 / 191
页数:6
相关论文
共 19 条
  • [1] ALTER HJ, 1989, CURRENT PERSPECTIVES, P83
  • [2] CALDWELL SH, 1993, AM J GASTROENTEROL, V88, P1016
  • [3] DAVIS GL, 1994, CLIN THER, V16, P334
  • [4] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506
  • [5] DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
  • [6] DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439
  • [7] HEPATITIS-C VIRUS GENOTYPES - AN INVESTIGATION OF TYPE-SPECIFIC DIFFERENCES IN GEOGRAPHIC ORIGIN AND DISEASE
    DUSHEIKO, G
    SCHMILOVITZWEISS, H
    BROWN, D
    MCOMISH, F
    YAP, PL
    SHERLOCK, S
    MCINTYRE, N
    SIMMONDS, P
    [J]. HEPATOLOGY, 1994, 19 (01) : 13 - 18
  • [8] HEPATITIS-C VIRUS AND PORPHYRIA-CUTANEA-TARDA - EVIDENCE OF A STRONG ASSOCIATION
    FARGION, S
    PIPERNO, A
    CAPPELLINI, MD
    SAMPIETRO, M
    FRACANZANI, AL
    ROMANO, R
    CALDARELLI, R
    MARCELLI, R
    VECCHI, L
    FIORELLI, G
    [J]. HEPATOLOGY, 1992, 16 (06) : 1322 - 1326
  • [9] HIGH PREVALENCE OF HEPATITIS-C INFECTION IN AFRO-CARIBBEAN PATIENTS WITH TYPE-2 DIABETES AND ABNORMAL LIVER-FUNCTION TESTS
    GRAY, H
    WREGHITT, T
    STRATTON, IM
    ALEXANDER, GJM
    TURNER, RC
    ORAHILLY, S
    [J]. DIABETIC MEDICINE, 1995, 12 (03) : 244 - 249
  • [10] NON-A, NON-B POSTTRANSFUSION HEPATITIS - LOOKING BACK IN THE 2ND DECADE
    KORETZ, RL
    ABBEY, H
    COLEMAN, E
    GITNICK, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) : 110 - 115